Morpholino

MO1-caspa

ID
ZDB-MRPHLNO-120808-1
Name
MO1-caspa
Previous Names
None
Target
Sequence
5' - GCCATGTTTAGCTCAGGGCGCTGAC - 3'
Disclaimer
Although ZFIN verifies reagent sequence data, we recommend that you conduct independent sequence analysis before ordering any reagent.
Note
Translation-blocking MO.
Genome Resources
None
Target Location
Genomic Features
No data available
Expression
Gene expression in Wild Types + MO1-caspa
Phenotype
Phenotype resulting from MO1-caspa
Phenotype of all Fish created by or utilizing MO1-caspa
Phenotype Fish Conditions Figures
defense response to bacterium increased efficacy, abnormal AB/TL + MO1-caspa bacterial treatment by injection: Mycobacterium marinum Fig. 6 with image from Zhang et al., 2020
ceratohyal cartilage deformed, abnormal WT + MO1-caspa standard conditions Fig. 8 from Masumoto et al., 2003
hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal WT + MO1-caspa standard conditions Fig. 2 with image from Frame et al., 2020
pharyngeal arch cartilage disorganized, abnormal WT + MO1-caspa standard conditions Fig. 8 from Masumoto et al., 2003
ceratohyal cartilage inverted, abnormal WT + MO1-caspa standard conditions Fig. 8 from Masumoto et al., 2003
hematopoietic multipotent progenitor cell runx1 expression decreased amount, abnormal WT + MO1-caspa chemical treatment by environment: glucose Fig. 2 with image from Frame et al., 2020
embryonic viscerocranium morphogenesis disrupted, abnormal WT + MO1-caspa standard conditions Fig. 8 from Masumoto et al., 2003
Meckel's cartilage decreased thickness, abnormal WT + MO1-caspa standard conditions Fig. 8 from Masumoto et al., 2003
palatoquadrate cartilage deformed, abnormal WT + MO1-caspa standard conditions Fig. 8 from Masumoto et al., 2003
whole organism viability, abnormal WT + MO1-caspa standard conditions text only from Masumoto et al., 2003
Meckel's cartilage deformed, abnormal WT + MO1-caspa standard conditions Fig. 8 from Masumoto et al., 2003
palatoquadrate cartilage decreased thickness, abnormal WT + MO1-caspa standard conditions Fig. 8 from Masumoto et al., 2003
hematopoietic multipotent progenitor cell decreased amount, abnormal la2Tg + MO1-caspa standard conditions Fig. 2 with image from Frame et al., 2020
defense response to bacterium decreased efficacy, ameliorated dram1ibl53/ibl53 + MO1-caspa (AB/TL) bacterial treatment by injection: Mycobacterium marinum Fig. 6 with image from Zhang et al., 2020
Citations